This trial is a prospective, open label, randomized, multi-center study, with intra-subject paired- wound control, intended to assess the safety and preliminary efficacy of administering EVs derived from allogeneic MSCs
Study Details
Internal Title:
AGLE-102-101
PCH IRB Number:
IRB-23-345
Clinical Trials Government Identifier:
NCT04173650
Diagnoses & Treatments:
Mesenchymal stem cells, Recessive Dystrophic Epidermolysis Bullosa, EB
Study Type:
Clinical Trial
Eligibility:
6 years or older, diagnosis of Dystrophic EB with wounds with size between 10-50cm squared on arms, legs, or trunk
Enrollment Status:
Opening Soon
Phase:
I/II